Related Experiment Video

Updated: May 7, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention

Fuling Zhou1, Shan Meng, Huanjin Song

  • 1Department of Clinical Hematology, Affiliated No. 2 Hospital, Xi'an Jiaotong University, 157 West Five Road, Xi'an 710004, People's Republic of China; Department of Systems Biology, Unit 0950, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

Blood Reviews
|September 24, 2013
PubMed

Insights

Dickkopf-1 (DKK1) drives myeloma bone disease by disrupting bone remodeling. Targeting DKK1 with therapies like antibodies shows promise for treating this debilitating condition.

Area of Science:

  • Oncology
  • Bone Biology
  • Molecular Signaling

Background:

  • Myeloma bone disease (MBD) is a significant complication of plasma cell myeloma (PCM), characterized by osteolytic bone lesions.
  • Dickkopf-1 (DKK1), a Wnt signaling inhibitor, is highly expressed in myeloma cells and plays a key role in MBD pathogenesis.
  • DKK1 inhibits osteoblast function and promotes osteoclast activity, contributing to bone destruction.

Purpose of the Study:

  • To review recent advances in understanding DKK1 pathway signaling in MBD.
  • To explore therapeutic strategies targeting DKK1 for MBD intervention.

Main Methods:

  • Literature review of studies on DKK1, Wnt signaling, and MBD.
  • Analysis of preclinical and clinical data on DKK1-targeted therapies.

Main Results:

  • DKK1 is a critical mediator of bone destruction in MBD.
  • Therapeutic strategies targeting DKK1, including neutralizing antibodies, have shown encouraging clinical results.
  • These findings highlight the therapeutic potential of targeting DKK1.

Conclusions:

  • DKK1 is a significant therapeutic target for managing MBD.
  • Further development of DKK1-targeting agents holds promise for improving patient outcomes in PCM.
Keywords:
AntibodyDKK1Myeloma bone diseaseProteasome inhibitorVaccine

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...